FDA Arthritis Advisory Committee
Executive Summary
Will meet on Dec. 6 to discuss guidelines for analgestic drugs (see related T&G-1) and clinical requirements for topical OTC nonsteroidal anti-inflammatory drugs. The committee will also consider ICN's Oxsoralen (methoxalen) and J&J-Therakos' UVAR photophoresis devise for scleroderma. On Dec. 7, the committee will meet in closed session. The meeting begins at 8:30 a.m. at the Holiday Inn in Bethesda, Maryland.